Medexus Pharmaceuticals (TSE:MDP) Sets New 1-Year High – Should You Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP) reached a new 52-week high during trading on Monday . The stock traded as high as C$4.00 and last traded at C$4.00, with a volume of 56585 shares changing hands. The stock had previously closed at C$3.94.

Medexus Pharmaceuticals Stock Up 1.3%

The company’s fifty day moving average is C$3.09 and its 200 day moving average is C$2.89. The stock has a market cap of C$128.88 million, a PE ratio of -199.50 and a beta of 0.42.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.